Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.
You may also be interested in...
Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer
The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.
Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS
An FDA “complete response” letter says the REMS the firm submitted in September 2008 must be finalized and approved before the agency can act on the expanded indication.
Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS
An FDA “complete response” letter says the REMS the firm submitted in September 2008 must be finalized and approved before the agency can act on the expanded indication.